iQure Pharma Inc. announces the Appointment of Professor Thomas Rades as CMC Advisor

Delaware – April 2020, iQure Pharma Inc., a company dedicated to preclinical and early clinical development of Oncology and Central Nervous System (CNS) compounds, announced today that Professor Thomas Rades is joining the company to serve as Advisor for technical development and drug delivery for the entire iQure portfolio.

Prof. Rades has vast experience in technical development and drug delivery gained over more than 25 years in industry and academic research. He is currently holding the position of Research Chair in Pharmaceutical Design and Drug Delivery at the University of Copenhagen in Denmark.

About Professor Rades

Prof. Thomas Rades graduated with a Master’s in Pharmacy from the University of Hamburg, Germany, and obtained his PhD at the Technical University of Braunschweig, Germany. Prof. Rades has spent time in the industry at F. Hoffmann – La Roche in Switzerland and in academic research mostly in New Zealand and Denmark, where he collaborated successfully with colleagues across the globe. In 2014, he received an honorary doctorate from Åbo Academi University, Turku, Finland.

Prof. Rades has developed an international reputation for his research in the physical characterization of drugs in solid dosage forms as well as in vaccine delivery using nanoparticulate systems (both polymeric and lipid based). Prof. Rades has published more than 400 papers in international peer review journals as well as several book chapters, one book and applied for more than 14 patents.

His key research interests are in formulation and drug delivery and the physical characterizations in both solid and liquid crystalline matter. His research in both areas aims to improve drug therapy through appropriate formulation of medicines and to increase the understanding of the physico-chemical properties of drugs and medicines, which combines physical, chemical, and biological sciences and technology to optimally formulate drugs for use in humans as well as animals.

Dr. Peter Schiemann, Chairman of the Board: We are delighted that Thomas has decided to join our team and will help supervise our technical development activities, especially in drug delivery. This is a great step forward for iQure, as Thomas will be instrumental in helping the company make the right decisions when it comes to developing the right formulations for its APIs. Especially today with more sophisticated APIs, the right formulation can determine the difference between success and failure. iQure is looking forward to moving its compounds into development later this year, hoping to make a significant difference in patients’ lives.

iQ-007: Confirmation of Safety Profile and Second Indication by NINDS (US)

Delaware – January 2020, iQure Pharma Inc., a company dedicated to preclinical and early development of Oncology and Central Nervous System (CNS) compounds, announced today that their iQ-007 compound demonstrated an excellent safety and efficacy profile in tests performed by the NINDS ETSP, US. Results are in line with earlier findings and make iQ-007 an excellent candidate for Neuropathic Pain as lead indication and Epilepsy as secondary indication.

iQ-007

Novel, small molecule with an excellent Safety and Efficacy profile in Neuropathic Pain animal models. The compound exhibits the potential for a novel pain-relevant mode of action. One of the unique features of iQ-007 is its lack of sedation with an expanded spectrum of efficacy as an analgesic, anticonvulsant and anti-depressive agent. iQ-007 is currently entering pre-clinical development for painful Diabetic Peripheral Neuropathy as lead indication and Epilepsy as secondary indication.

About NINDS ETSP

The mission of the NINDS Epilepsy Therapy Screening Program (ETSP) is to encourage and facilitate the discovery of new therapeutic agents for the treatment of epilepsy disorders. These tests are performed at a contract facility based at the University of Utah on a blinded and confidential basis. Since its establishment in 1975, the program has made important contributions to the development of several FDA-approved drugs for epilepsy, including felbamate (Felbatol®), topirimate (Topamax®), lacosamide (Vimpat®), and retigabine (Potiga®).

Pawel Zolnierczyk, CEO

We are delighted to learn that ETSP’s experimental results in the area of Epilepsy confirmed iQ-007’s promising safety profile. ETSP is a prestigious organization, which, because it conducts its studies in a blinded setting, can be regarded as fully independent. Although we knew that iQ-007’s lead indication and promising profile was in Neuropathic Pain, learning that it has proven its potential to expand into the Epilepsy indication as well, is exciting news. We will continue to monitor the progress at ETSP closely and make sure we fully exploit iQ-007’s potential.

Chairman Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January

Chairman of the Board, Dr. Peter Schiemann, will participate at JPMorganBIO in San Francisco 12.-16. January